Tricida, Inc.

OTCPK:TCDA.Q Voorraadrapport

Marktkapitalisatie: US$580.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida Beheer

Beheer criteriumcontroles 3/4

De CEO Tricida is Gerrit Klaerner, benoemd in Aug2013, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.68M, bestaande uit 12.8% salaris en 87.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.68% van de aandelen van het bedrijf, ter waarde $ 3.93. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 9.5 jaar.

Belangrijke informatie

Gerrit Klaerner

Algemeen directeur

US$4.7m

Totale compensatie

Percentage CEO-salaris12.83%
Dienstverband CEO9.8yrs
Eigendom CEO0.7%
Management gemiddelde ambtstermijn4yrs
Gemiddelde ambtstermijn bestuur9.5yrs

Recente managementupdates

Recent updates

Seeking Alpha • Oct 19

Tricida enters $125M debt facility

Tricida (NASDAQ:TCDA) gets into a debt facility of $125M with Hercules Capital, provider of customized debt financing for companies in the life sciences and technology-related markets. Of the $125M, $100M will be available for drawdown at Tricida’s option subject to the achievement of certain milestones. Under the terms of the debt facility, $25M will be available for drawdown until December 31, 2022, subject to the announcement of positive data from the VALOR-CKD trial.  An additional $25M will be available for drawdown until the earlier of ten business days following the filing of the NDA for veverimer and September 15, 2023. An additional $50M will be available for drawdown until the earlier of ten business days following the FDA approval of veverimer and February 15, 2024. The loans bear interest at a floating per annum interest rate equal to the greater of either 8.75% or the lesser of 8.75% plus the prime rate as reported in The Wall Street Journal minus 6.25% and 10.25%.
Seeking Alpha • Sep 21

Tricida: Important Binary Event Coming Up

Summary TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on. There could be some quick upside in the next 30 odd days. Tricida (TCDA) has been doing wonderfully lately, over the last 12 months, but it is down considerably from its PDUFA highs. That was from two years ago, when I used to cover the stock. I recall buying some TCDA, making good money, and then losing some money on the shares I held on to, because their lead asset veverimer was handed a CRL. The stock is up these days not because the CRL was resolved, but because of a number of other small and large things. Let's first discuss the CRL, though. Then we will see what has been responsible for the stock’s sudden buoyancy. Veverimer is targeting metabolic acidosis in CKD or chronic kidney disease patients. In an earlier trial, after 12 weeks of treatment, TRC101 or veverimer was able to increase blood bicarbonate level of at least 4 milliequivalents per liter (mEq/L) or achieved a blood bicarbonate level in the normal range of 22 to 29 mEq/L in 59.2% patients, compared with 22.5% of them in the placebo group (p< 0.0001). However, one of veverimer’s major problem is the standardly used therapy for this indication, which you can buy in a bottle from a grocery store for a few bucks. This is bicarbonate of soda, and while there have been no industry-sponsored trials for obvious reasons, it has long been used by doctors to treat metabolic acidosis. Its problem is that too much sodium content in the blood can cause heart diseases, which is where veverimer has a great deal of utility with its completely different mechanism of action. However, the FDA was not convinced, and it issued a CRL, asking for, among other things: Additional data regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate. Whether the demonstrated effect size would be reasonably likely to predict clinical benefit. I discussed all this in an earlier article from two years ago. A summary of the CRL from the company management was here: “According to the CRL, the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit,” Tricida said. This was an accelerated approval, and the company was already conducting VALOR-CKD at that time as a confirmatory trial. After the CRL, they said that interim data from this trial could be used to provide the data required by the FDA. This trial was supposed to enroll ~1500 patients and topline in 2023-24. In May, the company did an “administrative stop” to this trial after enrolling 1480 patients last year, and after 237 patients reached a primary endpoint event — end-stage renal disease, renal death, or greater than or equal to 40% reduction in eGFR or estimated glomerular filtration rate — in the renal outcomes study. This was done to conserve their cash reserve, which will be near depleted this quarter. Moreover, the FDA seems to have agreed that this may work. As Phil Nadeau at Cowen explained: Assuming a true hazard ratio ((HR)) of 0.70, the trial would be 78% powered at 250 events. Switching from power to observed HR, VALOR-CKD could be successful at 250 events if the observed HR is 0.78. There is only a modest increase to 0.79 observed HR should 300 events be in the final analysis. This calculation on the observed HR required for significance is based on 300 simulations on trial outcomes.
Analyse-artikel • Sep 14

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Today we will run through one way of estimating the intrinsic value of Tricida, Inc. ( NASDAQ:TCDA ) by estimating the...
Analyse-artikel • Dec 14

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Investors who take an interest in Tricida, Inc. ( NASDAQ:TCDA ) should definitely note that the CFO & Executive VP...

Analyse CEO-vergoeding

Hoe is Gerrit Klaerner's beloning veranderd ten opzichte van Tricida's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2022n/an/a

-US$134m

Jun 30 2022n/an/a

-US$148m

Mar 31 2022n/an/a

-US$153m

Dec 31 2021US$5mUS$600k

-US$177m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$219m

Mar 31 2021n/an/a

-US$244m

Dec 31 2020US$9mUS$598k

-US$265m

Sep 30 2020n/an/a

-US$268m

Jun 30 2020n/an/a

-US$235m

Mar 31 2020n/an/a

-US$213m

Dec 31 2019US$10mUS$584k

-US$177m

Sep 30 2019n/an/a

-US$146m

Jun 30 2019n/an/a

-US$131m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$1mUS$503k

-US$103m

Sep 30 2018n/an/a

-US$96m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$60m

Dec 31 2017US$821kUS$425k

-US$41m

Compensatie versus markt: De totale vergoeding ($USD 4.68M ) Gerrit } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.15K ).

Compensatie versus inkomsten: De vergoeding van Gerrit is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Gerrit Klaerner (51 yo)

9.8yrs
Tenure
US$4,676,490
Compensatie

Dr. Gerrit Klaerner, Ph.D. Founded Tricida, Inc.and has been its Chief Executive Officer and President since August 2013 and has been its an Executive Director since July 2013. Dr. Klaerner was the Founder...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Gerrit Klaerner
Founder9.8yrsUS$4.68m0.68%
$ 3.9
Geoffrey Parker
COO, CFO & Executive VP6.2yrsUS$2.51m0.72%
$ 4.2
Robert McKague
Executive VP3.3yrsUS$2.43m0.031%
$ 0.2
Dawn Parsell
Executive Vice President of Clinical Development4.8yrsUS$2.77m0.0060%
$ 0.03
Annie Yoshiyama
VP of Finance & Chief Accounting Officer2.5yrsgeen gegevensgeen gegevens
Jackie Cossmon
Vice President of Investor Relations & Communicationsno datageen gegevensgeen gegevens
Edward Hejlek
Executive Vice President of Intellectual Property3.3yrsUS$2.10mgeen gegevens
4.0yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van TCDA.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Gerrit Klaerner
Founder9.9yrsUS$4.68m0.68%
$ 3.9
Kathryn Falberg
Independent Non-Employee Director5.1yrsUS$329.00k0.074%
$ 0.4
Klaus Veitinger
Independent Chairman of the Board9.3yrsUS$379.00k0.20%
$ 1.1
David Hirsch
Independent Non-Employee Director6.9yrsUS$326.50k0.019%
$ 0.1
Robert Alpern
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.7yrsUS$314.00kgeen gegevens
John Fordtran
Member of Scientific & Clinical Advisory Boardno datageen gegevensgeen gegevens
David Bushinsky
Member of Scientific & Clinical Advisory Boardno datageen gegevensgeen gegevens
Craig Hawker
Member of Scientific & Clinical Advisory Boardno datageen gegevensgeen gegevens
Sandra Coufal
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.9yrsUS$316.50k0.15%
$ 0.9
Navdeep Tangri
Member of Scientific & Clinical Advisory Boardno datageen gegevensgeen gegevens
Thomas Hostetter
Member of Scientific & Clinical Advisory Boardno datageen gegevensgeen gegevens
Bertram Pitt
Member of Scientific and Clinical Advisory Boardno datageen gegevensgeen gegevens
9.5yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TCDA.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2023/06/13 21:22
Aandelenkoers aan het einde van de dag2023/06/13 00:00
Inkomsten2022/09/30
Jaarlijkse inkomsten2021/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Tricida, Inc. wordt gevolgd door 3 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Dana FlandersGoldman Sachs
Jessica FyeJ.P. Morgan
Philip NadeauTD Cowen